newsfilter
← Latest News
PR Newswire·

Astellas and Kate Therapeutics Announce Exclusive License Agreement for KT430

KT430 is a preclinical, next-generation investigational gene therapy to treat X-linked myotubular myopathy (XLMTM) TOKYO and SAN DIEGO, June 8, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: